Nasdaq Cara News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq cara. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Cara Today - Breaking & Trending Today

Cara Therapeutics (NASDAQ:CARA) Share Price Crosses Below Two Hundred Day Moving Average of $1.33

Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report)’s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.33 and traded as low as $0.82. Cara Therapeutics shares last traded at $0.91, with a volume of 4,300,261 shares. Analysts Set […] ....

United States , Piper Sandler , Cara Therapeutics Inc , Allspring Global Investments Holdings , Needham Company , Jag Capital Management , Mirabella Financial Services , Sg Americas Securities , Cara Therapeutics , Get Free Report , Capital Management , Financial Services , Global Investments Holdings , Cara Therapeutics Daily , Nasdaq Cara ,

Cara Therapeutics (NASDAQ:CARA) PT Lowered to $5.00

Cara Therapeutics (NASDAQ:CARA – Get Free Report) had its target price lowered by investment analysts at Needham & Company LLC from $6.00 to $5.00 in a report released on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Other equities analysts have also issued reports about the stock. HC […] ....

United States , Piper Sandler , Needham Company , Jag Capital Management , Allspring Global Investments Holdings , Cara Therapeutics Company Profile , Sg Americas Securities , Mirabella Financial Services , Cara Therapeutics Inc , Cara Therapeutics , Get Free Report , Capital Management , Financial Services , Global Investments Holdings , Cara Therapeutics Daily , Nasdaq Cara , Lower Price Target , Needham Company Llc ,

Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of "Moderate Buy" by Analysts

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to […] ....

United States , Piper Sandler , Hermes Inc , Tower Research Capital , Cetera Advisor Networks , Needham Company , Cara Therapeutics Inc , Jag Capital Management , Sigma Securities , Cara Therapeutics , Get Free Report , Research Capital , Advisor Networks , Capital Management , Two Sigma Securities , Get Free , Cara Therapeutics Daily , Nasdaq Cara ,

Cara Therapeutics, Inc. (NASDAQ:CARA) Short Interest Up 15.2% in November

Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) was the recipient of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 3,420,000 shares, a growth of 15.2% from the October 31st total of 2,970,000 shares. Currently, 7.4% of the company’s shares are sold short. […] ....

United States , Piper Sandler , Stifel Nicolaus , Jag Capital Management , Needham Company , Cetera Advisor Networks , Sigma Securities , Hermes Inc , Tower Research Capital , Cara Therapeutics Inc , Cara Therapeutics , Get Free Report , Research Capital , Advisor Networks , Capital Management , Two Sigma Securities , Cara Therapeutics Daily , Nasdaq Cara ,